Team:BrownTwo/Implementation/syntf

From 2008.igem.org

(Difference between revisions)
Line 12: Line 12:
Modularity – in order to modify the design to limit the expression of a given gene of interest, one must study a gene pathway map and identify a single link between the gene of interest and a transcription factor that regulates the expression of that gene
Modularity – in order to modify the design to limit the expression of a given gene of interest, one must study a gene pathway map and identify a single link between the gene of interest and a transcription factor that regulates the expression of that gene
 +
 +
Stipulation:  If G is a transcription factor that is known to auto-regulate, one will have to alter the modeling to account for this situation.
modifications to current scheme:
modifications to current scheme:

Revision as of 07:53, 28 October 2008



The syn. trans. factor system designed by caroline & david. cite memory.

  • modularity
  • extensibility

The laboratory of Dr. Pamela Silver at Harvard developed synthetic transcription factors for the construction of a novel “memory device” in Saccharomyces cerevisiae. While the details of this device are not essential to understanding our own gene network, it is important to discuss the significance of these transcription factors to our design. A transcription factor is composed of a binding domain, which targets the protein either an activation domain or a repression domain, which

Transcription factors are composed of a standard activation or repression domain linked to a variable binding domain. The binding domain is chosen such that it matches. Other features of these . A handful of these parts were available in the Registry, but we found it necessary to


Modularity – in order to modify the design to limit the expression of a given gene of interest, one must study a gene pathway map and identify a single link between the gene of interest and a transcription factor that regulates the expression of that gene

Stipulation: If G is a transcription factor that is known to auto-regulate, one will have to alter the modeling to account for this situation.

modifications to current scheme:

  • Ribozyme switch inhibition to knockdown leakiness of Repressor#3 (this would need to designed so that the aptamer on the repressor #3 mRNA responds to Repressor #2 protein)
  • alternatively, could consider having the promoter for construct Y produce an shRNA instead of a repressor protein
  • need to consider the possibility for regulation on both levels of protein synthesis

Possible further modifications to these transcription factors include the use of different regulation domains,

Involves the consideration of multiple binding sites